| Peptidase Inhibition and Analysis | Lifetime | 428 | TW 3 | 98.40 |
| Protease and Inhibitor Mechanisms | Lifetime | 212 | TW 1 | 98.36 |
| Cancer-related molecular mechanisms research | Lifetime | 958 | TW 8 | 97.52 |
| Oral Health Pathology and Treatment | Lifetime | 204 | TW 6 | 98.06 |
| Biomarkers in Disease Mechanisms | Lifetime | 110 | TW 2 | 95.52 |
| Cancer Mechanisms and Therapy | Lifetime | 342 | TW 9 | 96.52 |
| Circular RNAs in diseases | Lifetime | 808 | TW 7 | 95.74 |
| Cell death mechanisms and regulation | Lifetime | 670 | TW 8 | 95.73 |
| Flavonoids in Medical Research | Lifetime | 121 | TW 8 | 93.87 |
| Phytochemical compounds biological activities | Lifetime | 321 | TW 8 | 94.77 |
| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 874 | TW 3 | 95.65 |
| Bioactive Compounds in Plants | Lifetime | 57 | TW 3 | 89.67 |
| Curcumin's Biomedical Applications | Lifetime | 479 | TW 8 | 89.96 |
| Enzyme function and inhibition | Lifetime | 721 | TW 4 | 89.90 |
| Tannin, Tannase and Anticancer Activities | Lifetime | 279 | TW 10 | 83.12 |
| Phytochemical Studies and Bioactivities | Lifetime | 872 | TW 15 | 84.96 |
| Mechanisms of cancer metastasis | Lifetime | 268 | TW 8 | 81.95 |
| Silymarin and Mushroom Poisoning | Lifetime | 307 | TW 3 | 80.07 |
| Inflammation biomarkers and pathways | Lifetime | 694 | TW 9 | 73.74 |
| Pomegranate: compositions and health benefits | Lifetime | 702 | TW 5 | 75.38 |
| Beetle Biology and Toxicology Studies | Lifetime | 299 | TW 9 | 69.34 |
| Connective Tissue Growth Factor Research | Lifetime | 874 | TW 44 | 71.78 |
| Andrographolide Research and Applications | Lifetime | 548 | TW 41 | 54.10 |
| Cell death mechanisms and regulation | 2021-2025 | 18 | TW 1 | 94.35 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 42 | TW 1 | 91.10 |
| Cancer-related molecular mechanisms research | 2021-2025 | 811 | TW 7 | 94.18 |
| Curcumin's Biomedical Applications | 2021-2025 | 75 | TW 2 | 90.76 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 473 | TW 4 | 89.54 |
| Cancer-related Molecular Pathways | 2021-2025 | 298 | TW 5 | 86.88 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 120 | TW 1 | 86.98 |
| Bioactive Compounds and Antitumor Agents | 2021-2025 | 180 | TW 1 | 84.58 |
| NF-κB Signaling Pathways | 2021-2025 | 76 | TW 3 | 79.28 |
| Ocular Surface and Contact Lens | 2021-2025 | 749 | TW 11 | 85.05 |
| Circadian rhythm and melatonin | 2021-2025 | 860 | TW 5 | 81.20 |
| Ocular Infections and Treatments | 2021-2025 | 518 | TW 11 | 71.32 |
| S100 Proteins and Annexins | 2021-2025 | 652 | TW 3 | 66.61 |
| Medicinal plant effects and applications | 2021-2025 | 187 | TW 2 | 64.13 |
| Mast cells and histamine | 2021-2025 | 930 | TW 4 | 61.63 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 523 | TW 8 | 54.35 |
| Proteoglycans and glycosaminoglycans research | 2021-2025 | 902 | TW 14 | 50.80 |
| Enzyme function and inhibition | 2021-2025 | 883 | TW 8 | 35.62 |
